Sfoglia per Autore
Adjuvant treatment of colorectal cancer in the elderly : where do we come from and where are we going?
2012 M. Di Bartolomeo, F. Pietrantonio, P. Biondani, F. De Braud
Hepatic colorectal cancer metastases showing a distinctive pattern of pathological response after metronomic capecitabine and bevacizumab
2012 F. Pietrantonio, P. Biondani, A. Pellegrinelli, A. Marchianò, K.F. Dotti, R. Buzzoni, M.D. Bartolomeo
Management of advanced genitourinary tumors
2012 F. Pietrantonio, P. Biondani, E. Verzoni, G. Procopio
Bax expression is predictive of favorable clinical outcome in chemonaive advanced gastric cancer patients treated with capecitabine, oxaliplatin, and irinotecan regimen
2012 F. Pietrantonio, P. Biondani, F. de Braud, A. Pellegrinelli, G. Bianchini, F. Perrone, B. Formisano, M. Di Bartolomeo
Is the standardized uptake value of FDG-PET/CT predictive of pathological complete response in locally advanced rectal cancer treated with capecitabine-based neoadjuvant chemoradiation?
2013 C. Bampo, A. Alessi, S. Fantini, G. Bertarelli, F. De Braud, E. Bombardieri, F. Valvo, F. Crippa, M. Di Bartolomeo, L. Mariani, M. Milione, P. Biondani, B. Avuzzi, C. Chiruzzi, F. Pietrantonio
A review on biomarkers for prediction of treatment outcome in gastric cancer
2013 F. Pietrantonio, F. De Braud, V. Da Prat, F. Perrone, M.A. Pierotti, M. Gariboldi, G. Fanetti, P. Biondani, A. Pellegrinelli, I. Bossi, M. Di Bartolomeo
Lack of Bax expression is associated with irinotecan-based treatment activity in advanced colorectal cancer patients
2013 F. Pietrantonio, P. Biondani, M. Milione, F. Melotti, G. Bertarelli, F. Perrone, F. De Braud, L. Mariani, G. Fanetti, D. Cortinovis, M. Di Bartolomeo
Role of BAX for outcome prediction in gastrointestinal malignancies
2013 F. Pietrantonio, P. Biondani, E. Ciurlia, G. Fanetti, A. Tessari, G. Bertarelli, I. Bossi, V. Musella, F. Melotti, M.D. Bartolomeo, F. Valvo, A. Pellegrinelli, M. Milione, F. Perrone, F. De Braud
Role of cMET in the development and progression of colorectal cancer
2013 J.C.S. Pérez-Vargas, P. Biondani, C. Maggi, M. Gariboldi, A. Gloghini, A. Inno, C.C. Volpi, A.V. Gualeni, M. di Bartolomeo, F. de Braud, A. Castano, I. Bossi, F. Pietrantonio
Single agent panitumumab in kras wild-type metastatic colorectal cancer patients following cetuximab-based regimens
2013 F. Pietrantonio, F. Perrone, P. Biondani, C. Maggi, A. Lampis, C. Bertan, F. Venturini, L. Tondulli, D. Ferrari, V. Ricci, F. Villa, G. Barone, N. Bianco, A. Ghidini, I. Bossi, G. Fanetti, M.D. Bartolomeo, F. De Braud
Safety profile and treatment response of everolimus in different solid tumors : an observational study
2014 E. Verzoni, S. Pusceddu, R. Buzzoni, E. Garanzini, A. Damato, P. Biondani, I. Testa, P. Grassi, E. Bajetta, F. Debraud, G. Procopio
Chronomodulated capecitabine and adjuvant radiation in intermediate-risk to high-risk rectal cancer : a phase II study
2014 E. Bajetta, F. Pietrantonio, R. Buzzoni, E. Ferrario, F. Valvo, L. Mariani, K.F. Dotti, P. Biondani, B. Formisano, A. Gevorgyan, P. Grassi, M. Di Bartolomeo
Rationale and protocol of RESORT, a randomized, open-label, multicenter phase II study to evaluate the efficacy of sorafenib in patients with advanced renal cell carcinoma after radical resection of the metastases
2014 G. Procopio, E. Verzoni, P. Biondani, P. Grassi, I. Testa, E. Garanzini, F. de Braud
Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT
2014 M. Di Bartolomeo, F. Pietrantonio, F. Perrone, K.F. Dotti, A. Lampis, C. Bertan, E. Beretta, L. Rimassa, C. Carbone, P. Biondani, R. Passalacqua, S. Pilotti, E. Bajetta
Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation
2014 F. Pietrantonio, F. Perrone, F. De Braud, A. Castano, C. Maggi, I. Bossi, A. Gevorgyan, P. Biondani, M. Pacifici, A. Busico, M. Gariboldi, F. Festinese, E. Tamborini, M. Di Bartolomeo
Targeted treatments in advanced renal cell carcinoma : focus on Axitinib
2014 E. Verzoni, P. Grassi, I. Testa, R. Iacovelli, P. Biondani, E. Garanzini, F. De Braud, G. Procopio
Sequential Tyrosine Kinase Inhibitors (TKIs) in metastatic renal cell carcinoma : results from a large cohort of patients
2014 P. Biondani, E. Verzoni, V. Torri, L. Porcu, P. Grassi, I. Testa, F. De Braud, G. Procopio
TP53 mutations in advanced colorectal cancer : the dark side of the moon
2014 F. Pietrantonio, P. Biondani, F. Perrone, M. Di Bartolomeo, M. Pacifici, M. Milione, F. Melotti, C. Maggi, G. Montemurro, I. Bossi, L. Mariani, F. De Braud
Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases
2015 F. Pietrantonio, V. Mazzaferro, R. Miceli, C. Cotsoglou, F. Melotti, G. Fanetti, F. Perrone, P. Biondani, C. Muscarà, M. Di Bartolomeo, J. Coppa, C. Maggi, M. Milione, E. Tamborini, F. de Braud
A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer
2015 F. Pietrantonio, G. Aprile, L. Rimassa, P. Franco, S. Lonardi, C. Cremolini, P. Biondani, E.L. Sbicego, F. Pasqualetti, G. Tomasello, M. Niger, M. Casagrande, M. Ghidini, R. Muni, S. Montrone, F. Bergamo, R. Berenato, C. Fontanella, S. Bozzarelli, R. Moretto, F. Battaglin, M. Di Bartolomeo, F. De Braud, R. Miceli
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile